4‑Hexylresorcinol inhibits osteoclastogenesis by suppressing the NF‑κB signaling pathway and reverses bone loss in ovariectomized mice

Yi,Wenkai; Liu,Tao; Gao,Xinfeng; Xie,Yonghua; Liu,Ming

doi:10.3892/etm.2021.9785

4‑Hexylresorcinol inhibits osteoclastogenesis by suppressing the NF‑κB signaling pathway and reverses bone loss in ovariectomized mice

Authors:
- Wenkai Yi
- Tao Liu
- Xinfeng Gao
- Yonghua Xie
- Ming Liu
View Affiliations

Affiliations: Department of Spine Surgery, Pu Ai Hospital of Wuhan City, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, P.R. China
Published online on: February 11, 2021 https://doi.org/10.3892/etm.2021.9785
Article Number: 354
Copyright: © Yi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

4‑Hexylresorcinol (4HR) is a small organic compound that is widely used as an antiseptic and antioxidant. In the present study, its role in osteoclastogenesis was investigated. Bone marrow‑derived macrophages from mice were used to examine the role of 4HR in osteogenesis. An ovariectomy (OVX) mouse model was constructed to examine the effect of 4HR in vivo, followed by hematoxylin and eosin and tartrate resistant acid phosphatase staining. In the present study, 4HR effectively suppressed receptor activator of NF‑κB ligand‑induced osteoclastogenesis in a dose‑dependent manner. 4HR was also found to significantly suppress the expression of osteoclast (OC)‑specific markers, including tartrate‑resistant acid phosphatase, cathepsin K, nuclear factor of activated T‑cell cytoplasmic 1 and c‑Fos in the presence of RANKL in BMMs. Furthermore, 4HR inhibited osteoclastogenesis by inhibiting the activation of the NF‑κB signaling pathway in BMMs. Consistent with the in vitro results, 4HR effectively ameliorated OVX‑induced bone loss and markedly reduced OC number in the proximal tibia in vivo. In conclusion, the present results suggested that 4HR inhibited osteoclastogenesis in vitro and rescued bone loss in vivo, suggesting that 4HR may serve as a novel therapeutic agent for osteoporosis treatment.

View Figures

View References

1	Kanis JA: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report. WHO study group. Osteoporos Int. 4:368–381. 1994.PubMed/NCBI View Article : Google Scholar
2	Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B and Kanis JA: Osteoporosis in the European union: Medical management, epidemiology and economic burden. A report prepared in collaboration with the international osteoporosis foundation (IOF) and the European federation of pharmaceutical industry associations (EFPIA). Arch Osteoporos. 8(136)2013.PubMed/NCBI View Article : Google Scholar
3	Tom SE, Adachi JD, Anderson FA Jr, Boonen S, Chapurlat RD, Compston JE, Cooper C, Gehlbach SH, Greenspan SL, Hooven FH, et al: Frailty and fracture, disability, and falls: A multiple country study from the global longitudinal study of osteoporosis in women. J Am Geriatr Soc. 61:327–334. 2013.PubMed/NCBI View Article : Google Scholar
4	Johnell O and Kanis J: Epidemiology of osteoporotic fractures. Osteoporos Int. 16 (Suppl 2):S3–S7. 2005.PubMed/NCBI View Article : Google Scholar
5	Eriksen EF: Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord. 11:219–227. 2010.PubMed/NCBI View Article : Google Scholar
6	Chen X, Wang Z, Duan N, Zhu G, Schwarz EM and Xie C: Osteoblast-osteoclast interactions. Connect Tissue Res. 59:99–107. 2018.PubMed/NCBI View Article : Google Scholar
7	Kikuta J and Ishii M: Bone imaging: Osteoclast and osteoblast dynamics. Methods Mol Biol. 1763:1–9. 2018.PubMed/NCBI View Article : Google Scholar
8	Roodman GD: Cell biology of the osteoclast. Exp Hematol. 27:1229–1241. 1999.PubMed/NCBI View Article : Google Scholar
9	Datta HK, Ng WF, Walker JA, Tuck SP and Varanasi SS: The cell biology of bone metabolism. J Clin Pathol. 61:577–587. 2008.PubMed/NCBI View Article : Google Scholar
10	Zaidi M: Skeletal remodeling in health and disease. Nat Med. 13:791–801. 2007.PubMed/NCBI View Article : Google Scholar
11	Trouvin AP and Goëb V: Receptor activator of nuclear factor-κB ligand and osteoprotegerin: Maintaining the balance to prevent bone loss. Clin Interv Aging. 5:345–354. 2010.PubMed/NCBI View Article : Google Scholar
12	Boyce BF and Xing L: Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 473:139–146. 2008.PubMed/NCBI View Article : Google Scholar
13	Lewiecki EM: Denosumab: A promising drug for the prevention and treatment of osteoporosis. Womens Health (Lond). 2:517–525. 2006.PubMed/NCBI View Article : Google Scholar
14	Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, Reid IR, Resch H, Siris E, Uebelhart D, et al: Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res. 26:530–537. 2011.PubMed/NCBI View Article : Google Scholar
15	Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J and Bone HG: Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 25:72–81. 2010.PubMed/NCBI View Article : Google Scholar
16	Gupta G and Aronow WS: Treatment of postmenopausal osteoporosis. Compr Ther. 33:114–119. 2007.PubMed/NCBI View Article : Google Scholar
17	Lewiecki EM: Denosumab in postmenopausal osteoporosis: What the clinician needs to know. Ther Adv Musculoskelet Dis. 1:13–26. 2009.PubMed/NCBI View Article : Google Scholar
18	Silva I and Branco JC: Denosumab: Recent update in postmenopausal osteoporosis. Acta Reumatol Port. 37:302–313. 2012.PubMed/NCBI
19	Kim MK, Yoon CS, Kim SG, Park YW, Lee SS and Lee SK: Effects of 4-hexylresorcinol on protein expressions in RAW 264.7 cells as determined by immunoprecipitation high performance liquid chromatography. Sci Rep. 9(3379)2019.PubMed/NCBI View Article : Google Scholar
20	Rabbani GH, Gilman RH, Kabir I and Mondel G: The treatment of fasciolopsis buski infection in children: A comparison of thiabendazole, mebendazole, levamisole, pyrantel pamoate, hexylresorcinol and tetrachloroethylene. Trans R Soc Trop Med Hyg. 79:513–515. 1985.PubMed/NCBI View Article : Google Scholar
21	Kim SG, Lee SW, Park YW, Jeong JH and Choi JY: 4-hexylresorcinol inhibits NF-κB phosphorylation and has a synergistic effect with cisplatin in KB cells. Oncol Rep. 26:1527–1532. 2011.PubMed/NCBI View Article : Google Scholar
22	He J, Zhu Q, Dong X, Pan H, Chen J and Zheng ZP: Oxyresveratrol and ascorbic acid O/W microemulsion: Preparation, characterization, anti-isomerization and potential application as antibrowning agent on fresh-cut lotus root slices. Food Chem. 214:269–276. 2017.PubMed/NCBI View Article : Google Scholar
23	Choi KH, Kim DW, Lee SK, Kim SG and Kim TW: The administration of 4-hexylresorcinol accelerates orthodontic tooth movement and increases the expression level of bone turnover markers in ovariectomized rats. Int J Mol Sci. 21(1526)2020.PubMed/NCBI View Article : Google Scholar
24	Zhao L, Guan H, Song C, Wang Y, Liu C, Cai C, Zhu H, Liu H, Zhao L and Xiao J: YAP1 is essential for osteoclastogenesis through a TEADs-dependent mechanism. Bone. 110:177–186. 2018.PubMed/NCBI View Article : Google Scholar
25	Bae S, Lee MJ, Mun SH, Giannopoulou EG, Yong-Gonzalez V, Cross JR, Murata K, Giguère V, van der Meulen M and Park-Min KH: MYC-dependent oxidative metabolism regulates osteoclastogenesis via nuclear receptor ERRα. J Clin Invest. 127:2555–2568. 2017.PubMed/NCBI View Article : Google Scholar
26	Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:156–159. 1987.PubMed/NCBI View Article : Google Scholar
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
28	Sun X, Gao X, Deng Z, Zhang L, McGilvray K, Gadomski BC, Amra S, Bao G and Huard J: High bone microarchitecture, strength, and resistance to bone loss in MRL/MpJ mice correlates with activation of different signaling pathways and systemic factors. FASEB J. 34:789–806. 2020.PubMed/NCBI View Article : Google Scholar
29	Farahzadi R, Fathi E and Vietor I: Mesenchymal stem cells could be considered as a candidate for further studies in cell-based therapy of alzheimer's disease via targeting the signaling pathways. ACS Chem Neurosci. 11:1424–1435. 2020.PubMed/NCBI View Article : Google Scholar
30	Deng Y, Lu J, Li W, Wu A, Zhang X, Tong W, Ho KK, Qin L, Song H and Mak KK: Reciprocal inhibition of YAP/TAZ and NF-κB regulates osteoarthritic cartilage degradation. Nat Commun. 9(4564)2018.PubMed/NCBI View Article : Google Scholar
31	Idris AI: Ovariectomy/orchidectomy in rodents. Methods Mol Biol. 816:545–551. 2012.PubMed/NCBI View Article : Google Scholar
32	Huo J and Sun X: Effect of astragalus polysaccharides on ovariectomy-induced osteoporosis in mice. Genet Mol Res. 15:2016.PubMed/NCBI View Article : Google Scholar
33	Gao X, Usas A, Tang Y, Lu A, Tan J, Schneppendahl J, Kozemchak AM, Wang B, Cummins JH, Tuan RS and Huard J: A comparison of bone regeneration with human mesenchymal stem cells and muscle-derived stem cells and the critical role of BMP. Biomaterials. 35:6859–6870. 2014.PubMed/NCBI View Article : Google Scholar
34	Lee Y, Kim HJ, Park CK, Kim YG, Lee HJ, Kim JY and Kim HH: MicroRNA-124 regulates osteoclast differentiation. Bone. 56:383–389. 2013.PubMed/NCBI View Article : Google Scholar
35	Takada J, Dinavahi R, Miyauchi A, Hamaya E, Hirama T, Libanati C, Nakamura Y, Milmont CE and Grauer A: Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: A post hoc analysis of the STRUCTURE trial. J Bone Miner Metab. 38:310–315. 2020.PubMed/NCBI View Article : Google Scholar
36	Xu S, Zhang Y, Wang J, Li K, Tan K, Liang K, Shen J, Cai D, Jin D, Li M, et al: TSC1 regulates osteoclast podosome organization and bone resorption through mTORC1 and Rac1/Cdc42. Cell Death Differ. 25:1549–1566. 2018.PubMed/NCBI View Article : Google Scholar
37	Zhang Y, Xu S, Li K, Tan K, Liang K, Wang J, Shen J, Zou W, Hu L, Cai D, et al: mTORC1 inhibits NF-κB/NFATc1 signaling and prevents osteoclast precursor differentiation, in vitro and in mice. J Bone Miner Res. 32:1829–1840. 2017.PubMed/NCBI View Article : Google Scholar
38	Lorenzo J, Horowitz M and Choi Y: Osteoimmunology: Interactions of the bone and immune system. Endocr Rev. 29:403–440. 2008.PubMed/NCBI View Article : Google Scholar
39	Lin TH, Pajarinen J, Lu L, Nabeshima A, Cordova LA, Yao Z and Goodman SB: NF-κB as a therapeutic target in inflammatory-associated bone diseases. Adv Protein Chem Struct Biol. 107:117–154. 2017.PubMed/NCBI View Article : Google Scholar
40	Abu-Amer Y: NF-κB signaling and bone resorption. Osteoporos Int. 24:2377–2386. 2013.PubMed/NCBI View Article : Google Scholar
41	Liu TT, Liu DM, Xuan Y, Zhao L, Sun LH, Zhao DD, Wang XF, He Y, Guo XZ, Du R, et al: The association between the baseline bone resorption marker CTX and incident dysglycemia after 4 years. Bone Res. 5(17020)2017.PubMed/NCBI View Article : Google Scholar
42	Thurairaja R, Iles RK, Jefferson K, McFarlane JP and Persad RA: Serum amino-terminal propeptide of type 1 procollagen (P1NP) in prostate cancer: A potential predictor of bone metastases and prognosticator for disease progression and survival. Urol Int. 76:67–71. 2006.PubMed/NCBI View Article : Google Scholar
43	Boyle WJ, Simonet WS and Lacey DL: Osteoclast differentiation and activation. Nature. 423:337–342. 2003.PubMed/NCBI View Article : Google Scholar
44	Boyce BF, Xiu Y, Li J, Xing L and Yao Z: NF-κB-mediated regulation of osteoclastogenesis. Endocrinol Metab (Seoul). 30:35–44. 2015.PubMed/NCBI View Article : Google Scholar
45	Silva I and Branco JC: Rank/Rankl/opg: Literature review. Acta Reumatol Port. 36:209–218. 2011.PubMed/NCBI
46	Onal M, Xiong J, Chen X, Thostenson JD, Almeida M, Manolagas SC and O'Brien CA: Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem. 287:29851–29860. 2012.PubMed/NCBI View Article : Google Scholar
47	Salamanna F, Borsari V, Contartese D, Nicoli Aldini N and Fini M: Link between estrogen deficiency osteoporosis and susceptibility to bone metastases: A way towards precision medicine in cancer patients. Breast. 41:42–50. 2018.PubMed/NCBI View Article : Google Scholar
48	Kanis JA, Cooper C, Rizzoli R and Reginster JY: Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 30:3–44. 2019.PubMed/NCBI View Article : Google Scholar